The new England Journal of Medicine of Medicine published the results of a new corona clinical trial of Gilead’s antiviral drug remdesivir on Friday. In Phase 3 clinical trials, Redcievir was shown to reduce recovery time in infected people from 15 days to 11 days.
1,059 new crown patients in 60 different locations in the United States, Europe and Asia participated in the trial, 538 patients took a 10-day course of ritthivir, and 521 patients received placebo treatment. The researchers assessed patients daily to determine the severity of the symptoms and the possible side effects of the drug.
In the placebo group, Redciewe shortened the recovery time. Patients who took the drug later after the onsgoing symptoms of the new coronal symptoms (e.g. after 10 days) responded to the drug better than those who took the drug earlier.
Patients who took rhaidsivir died less than the placebo group, but the difference between the two sides may not be statistically significant (21 vs. 28). By contrast, the drug, hydroxychloroquine, which President Trump has championed, increases mortality.